Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Inclusion Criteria:

1. Provision of signed and dated written informed consent prior to any study-specificprocedures.

2. Adults aged 18-75, inclusive when signing the informed consent.

3. Documented physician-diagnosis of asthma for at least 12 months.

4. Treated with medium or high dose ICS in combination with LABA.

5. Demonstration of uncontrolled asthma through ACQ-6 score ≥ 1.5 .

6. Pre-bronchodilator FEV1 ≥ 40% to ≤ 90% of predicted normal.

7. Documented exacerbation history in the last 12 months and biomarker requirements of:

8. 2 severe exacerbations OR

9. 1 severe exacerbation and:

(i) Eosinophils ≥ 150 cells/µl or (ii) FeNo ≥ 25 ppb

8. Participants need to demonstrate a ≥70% compliance for Asthma Daily Diary.

9. Women of Child Bearing Potential (WOCBP) must have a negative pregnancy test.

10. Contraceptive use by males and females should be consistent with local regulationsregarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

1. Completed treatment for respiratory infection with antibiotics in the 4 weeks priorto Visit 1.

2. Clinically significant pulmonary disease other than asthma .

3. Current smokers, former smokers with >10 pack-years history.

4. Clinically significant aortic stenosis or pulmonary arterial hypertension.

5. Active tuberculosis, hepatitis, HIV, or current diagnosis of cancer or immunecomplex disease.

6. Unstable cardiovascular disorders.